Eli Lilly has put another clear gap between itself and Novo Nordisk. On 28 October the company reported that retatrutide, its experimental once-weekly injection, beat Ozempic at its highest approved dose on both blood sugar control and weight loss in a Phase 3 trial of 1,298 adults with type 2 diabetes.
After 80 weeks, patients on either dose of retatrutide saw their A1C, the standard measure of long-term blood sugar, fall by 2.2 percentage points. Ozempic 2 mg lowered it by 1.8 points. The weight results were more striking: 19.5% of body weight lost on the 9 mg dose and 20.9% on 12 mg, against 9.4% on Ozempic. Lilly plans to file for US approval in the first quarter of 2027.
Why This Trial Matters More Than Most
Retatrutide works on three hormone receptors (GLP-1, GIP and glucagon), where Ozempic works on one and Lilly’s own Mounjaro on two. Earlier studies had compared retatrutide with a placebo. This is the first time it has been tested directly against a rival incretin medicine, and the margin is wide enough that doctors and insurers will notice.
The study, called TRANSCEND-T2D-2, was open-label, meaning patients and doctors knew which drug was being given. That is a known weakness and full peer-reviewed data are still to come. There were also more side effects. Diarrhoea was more common on retatrutide, a skin sensation called dysaesthesia was reported in 4.8% to 6.5% of patients against 2.7% on Ozempic, and 7.9% of retatrutide patients stopped treatment because of adverse events, roughly three times the Ozempic rate.
Investors took the result as a modest win for Lilly rather than a surprise. Lilly shares rose by around 1% to 2% on 28 October, while Novo Nordisk’s US-listed shares slipped about 1.5%. Novo has now lost several head-to-head comparisons with Lilly, and the gap in its pipeline is becoming a question its management must answer when it reports nine-month results on 4 November.
A Two-Company Market With Pricing Power
The commercial picture matters as much as the science. Obesity and diabetes drugs are already among the biggest-selling medicines in the world, and the market remains effectively controlled by two companies. Each new generation that shows greater weight loss gives its maker a fresh reason to defend premium prices, even as governments push back. The US administration’s most-favoured-nation pricing schemes and Medicare’s negotiated prices are aimed squarely at this category.
For anyone who pays for these drugs, the likely result is not cheaper treatment but a wider menu at several price points. Older medicines will face discounting and, eventually, generic competition, while the newest products such as retatrutide will arrive with the highest list prices and the strongest clinical case for using them.
The BusinessIQˣ View: What Leaders Should Do About It
The impact. Employers that fund health benefits sit closest to this story. GLP-1 spending is already one of the fastest-rising lines in many corporate health plans, and a drug that delivers 20% weight loss will drive demand rather than dampen it. Insurers, pharmacy benefit managers and self-insured companies in the US, and private medical schemes elsewhere, face the sharpest cost exposure. Food, fitness, apparel and medical device businesses should also note that a growing share of their customers will be on these medicines.
What to do now:
1. Ask your benefits adviser or insurer for your current GLP-1 spend, how it has grown over two years, and what their model assumes once retatrutide reaches the market in 2027 or 2028.
2. Review the coverage rules in your health plan before renewal. Decide whether you want prior authorisation, step therapy that starts with lower-cost options, or coverage tied to a lifestyle or clinical programme.
3. Put outcome data on the table. Ask providers to show what your plan is getting for the money in reduced absence, fewer related claims and staff retention, not just prescriptions filled.
4. If you sell food, drink, fitness or clothing, test what customers on these drugs buy differently. Smaller portions, higher-protein products and changing clothing sizes are already showing up in retail data.
5. Investors and boards with healthcare exposure should treat the Lilly and Novo pipelines as a single market story. Pricing policy in Washington may move these shares as much as trial results.
Retatrutide is not yet approved, and the side effect profile still has to win over regulators and doctors. But the direction is clear: these medicines are getting stronger, and the bill for them is not about to shrink.
